These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 7753456

  • 41. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K, Gerasimidis T, Verdy E, Elalamy I, Samama MM, Gerotziafas GT.
    Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
    [Abstract] [Full Text] [Related]

  • 42. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ, Shi XB, Yang JG, Hu DY.
    Chin Med J (Engl); 2009 May 20; 122(10):1199-202. PubMed ID: 19493471
    [Abstract] [Full Text] [Related]

  • 43. Use of low molecular weight heparin in pregnancy.
    Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar VV.
    Thromb Haemost; 1992 Dec 07; 68(6):652-6. PubMed ID: 1337628
    [Abstract] [Full Text] [Related]

  • 44. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
    Harenberg J, Malsch R, Angelescu M, Lange C, Michaelis HC, Wolf H, Heene DL.
    Blood Coagul Fibrinolysis; 1996 Jun 07; 7(4):477-83. PubMed ID: 8840001
    [Abstract] [Full Text] [Related]

  • 45. [Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk].
    Steinbach G, Bosc C, Caraman PL, Azoulay E, Olry L, D'Azemar P, Chopin J.
    Nephrologie; 1990 Jun 07; 11(1):17-21. PubMed ID: 2165223
    [Abstract] [Full Text] [Related]

  • 46. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Lane DA, Ireland H, Tew CJ, Flynn A, Curtis JR.
    Acta Chir Scand Suppl; 1988 Jun 07; 543():101-4. PubMed ID: 2847457
    [Abstract] [Full Text] [Related]

  • 47. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P, Bach J, Simon M, Saggau W.
    J Extra Corpor Technol; 2007 Jun 07; 39(2):81-6. PubMed ID: 17672188
    [Abstract] [Full Text] [Related]

  • 48. Central venous catheter sampling of low molecular heparin levels: an approach to increasing result reliability.
    Bauman ME, Belletrutti M, Bauman ML, Massicotte MP.
    Pediatr Crit Care Med; 2012 Jan 07; 13(1):1-5. PubMed ID: 21317677
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y.
    Am J Kidney Dis; 2008 May 07; 51(5):789-95. PubMed ID: 18436089
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Detection and neutralisation of heparin by a fluorescent ruthenium compound.
    Szelke H, Harenberg J, Krämer R.
    Thromb Haemost; 2009 Nov 07; 102(5):859-64. PubMed ID: 19888520
    [Abstract] [Full Text] [Related]

  • 55. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
    Mouton C, Calderon J, Janvier G, Vergnes MC.
    Thromb Res; 2003 Nov 07; 111(4-5):273-9. PubMed ID: 14693175
    [Abstract] [Full Text] [Related]

  • 56. Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin.
    Castro-López V, Murray B, Harris LF, O'Donnell JS, Killard AJ.
    Blood Coagul Fibrinolysis; 2012 Jan 07; 23(1):98-103. PubMed ID: 22089943
    [Abstract] [Full Text] [Related]

  • 57. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
    Rosenberg AF, Zumberg M, Taylor L, LeClaire A, Harris N.
    J Pharm Pract; 2010 Jun 07; 23(3):210-6. PubMed ID: 21507816
    [Abstract] [Full Text] [Related]

  • 58. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M.
    Arch Intern Med; 1994 Jan 10; 154(1):49-56. PubMed ID: 8267489
    [Abstract] [Full Text] [Related]

  • 59. Anti-factor Xa (anti-Xa) assay.
    Newall F.
    Methods Mol Biol; 2013 Jan 10; 992():265-72. PubMed ID: 23546719
    [Abstract] [Full Text] [Related]

  • 60. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.
    Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Köstering H, Seidel D, Scheler F.
    Kidney Int; 1988 Apr 10; 33(4):890-6. PubMed ID: 2838681
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.